IVI and Germany
German Leadership at IVI
Dr. Ralf Clemens, Principal and Founder of Grid Europe Consulting (2018-present)
Professor Fred Zepp, University Medical Center of the Johannes Gutenberg University Mainz (2018-2020)
Professor Stefan Kaufmann, Max Planck Institute for Infection Biology (2001; 2005-2006)
IVI Leadership Team
Dr. Florian Marks, Deputy Director General of Epidemiology, Public Health, Impact (EPIC)
Ongoing Collaboration
Institute for Tropical Medicine at University Tübingen
IVI collaborates with the Institute for Tropical Medicine at University Tübingen on Vaccine Against Schistosomiasis for Africa (VASA), a consortium formed in 2019 by IVI and the University of Cambridge to assess the safety and immunogenicity of the SchistoShield® vaccine developed by PAI Life Sciences Inc.
In 2024, the project completed a seroepidemiology study, a controlled human infection model study, and a Phase Ib clinical trial at its Madagascar site to assess the safety and reactogenicity of the SchistoShield® vaccine.
Capturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia (CAPTURA)
University of Heidelberg is one of the collaborators for the IVI-led CAPTURA project, which played a pivotal role in expanding historical and current datasets on AMR and antimicrobial usage through extensive data collection efforts across 12 countries of Southeast and South Asia. By building a network of laboratories and pharmacies for data sharing and identifying human health facilities that are generating AMU and AMR data, CAPTURA is helping to both establish and expand surveillance in Asian countries while unifying their efforts.
Bernhard Nocht Institute for Tropical Medicine
Bernard Nocht Institute for Tropical Medicine is a collaborator for ARC-WA project (Advancing Research Capacity in West Africa (ARC-WA) where IVI collaborates with CEPI and several other research organizations to establish a network of Good Clinical Practice-compliant clinical trial sites in West Africa, ready to respond to future health emergencies.
Previous Collaboration
Federal Ministry of Health (BMG)
The German Federal Ministry of Health is funding IVI’s Real-time Tracking of Neglected Bacterial Diseases and Resistance Patterns in Asia (TuNDRA) Plus program, which has identified the bacterial and viral etiology of febrile and respiratory diseases in hospitalized children and examined trends in bacterial antimicrobial resistance (AMR) in Bangladesh, Cambodia, and Viet Nam.
Robert Koch Institute
IVI collaborates with the Robert Koch Institute on the TuNDRA Plus program.
Dengue Vaccines with the Federal Ministry of Education and Research (BMBF)
BMBF was a major donor to IVI from 2014 to 2018. BMBF provided grants to IVI’s Dengue Vaccine Initiative, which covered technical assistance and support to Instituto Butantan of Brazil and Vabiotech of Viet Nam for the development of their dengue vaccine candidates.
North Korea Vaccination Campaign with Caritas Germany
In 2013, IVI supported a Japanese encephalitis vaccination campaign coordinated by Caritas Germany and the North Korean Ministry of Public Health (MOPH) in which over 3 million children were immunized. The campaign was part of IVI’s collaborated effort with the North Korean Academy of Medical Science (AMS) to reduce the burden of diarrheal disease and acute encephalitis syndrome (AES) among children in North Korea.
Else Kröner-Fresenius-Stiftung
In 2013, IVI received funding from the Else Kröner-Fresenius Foundation to conduct capacity-building activities in Burkina Faso and Madagascar, two of the Typhoid Surveillance in sub-Saharan Africa Program (TSAP) host countries.
Sartorius AG
Sartorius AG was a major donor to IVI in the early years of its establishment, providing over €575,000 in funding to the Institute.
Sartorius AG sponsored IVI’s Annual International Course on Vaccinology (2004-2005) and annual training courses for professionals in developing countries on the clinical evaluation of vaccines.
Sartorius AG was a donor to the Diseases of the Most Impoverished (DOMI) program, launched by IVI in 2000 with the aim of accelerating the development and introduction of vaccines against cholera, typhoid fever, and shigellosis in areas where these diseases are endemic.
Bernhard Nocht Institute for Tropical Medicine
IVI collaborated with the Bernhard Nocht Institute on IVI’s Salmonella Vaccine Program, which aims to accelerate development of an injectable, trivalent vaccine for typhoid and invasive non-typhoidal Salmonella (iNTS). In September 2018, IVI initiated preclinical work on the iNTS vaccine. Cell banks were generated for iNTS clinical isolates from IVI’s TSAP surveillance program that had been stored at the Bernhard Nocht Institute.